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ABSTRACT
Objectives The imbalance between effector and
regulatory T (Treg) cells is crucial in the pathogenesis of
autoimmune arthritis. Immune responses are often
investigated in the blood because of its accessibility, but
circulating lymphocytes are not representative of those
found in inflamed tissues. This disconnect hinders our
understanding of the mechanisms underlying disease.
Our goal was to identify Treg cells implicated in
autoimmunity at the inflamed joints, and also readily
detectable in the blood upon recirculation.
Methods We compared Treg cells of patients with
juvenile idiopathic arthritis responding or not to therapy
by using: (i) T cell receptor (TCR) sequencing, to identify
clonotypes shared between blood and synovial fluid; (ii)
FOXP3 Treg cell-specific demethylated region DNA
methylation assays, to investigate their stability and (iii)
flow cytometry and suppression assays to probe their
tolerogenic functions.
Results We found a subset of synovial Treg cells that
recirculated into the bloodstream of patients with
juvenile idiopathic and adult rheumatoid arthritis. These
inflammation-associated (ia)Treg cells, but not other
blood Treg cells, expanded during active disease and
proliferated in response to their cognate antigens.
Despite the typical inflammatory-skewed balance of
immune mechanisms in arthritis, iaTreg cells were stably
committed to the regulatory lineage and fully
suppressive. A fraction of iaTreg clonotypes were in
common with pathogenic effector T cells.
Conclusions Using an innovative antigen-agnostic
approach, we uncovered a population of bona fide
synovial Treg cells readily accessible from the blood and
selectively expanding during active disease, paving the
way to non-invasive diagnostics and better
understanding of the pathogenesis of autoimmunity.
INTRODUCTION
T cell-mediated autoimmunity occurs when check-
points of peripheral tolerance, including suppres-
sion by CD4+CD25+FOXP3+ regulatory T cells
(Treg cells), fail to delete or otherwise inactivate
self-reactive clonotypes.1 Treg cells can either
develop in the thymus or differentiate from periph-
eral naive T cells stimulated under tolerogenic con-
ditions;2 in either case, the expression of the
transcription factor FOXP3 is essential for their
development and suppressive function.3–5
Autoimmune rheumatic diseases, including both
the adult form—rheumatoid arthritis (RA)—and
the juvenile form—oligoarticular and polyarticular
juvenile idiopathic arthritis ( JIA)—are characterised
by chronic joint inflammation and accumulation of
autoreactive T cells in the synovium, with conse-
quent tissue damage and joint degeneration.6 In
recent years, it has become increasingly clear that
failure of immune tolerance in rheumatic diseases is
due to an imbalance between effector and regula-
tory mechanisms.7 8
On the effector side, T cells from the inflamed
joints are resistant to Treg cell-mediated suppres-
sion thanks to protein kinase B (PKB) hyperactiva-
tion in JIA.9 10 In addition, we recently described a
subset of circulating antigen-experienced, proin-
flammatory effector T (Teff) cells that are resistant
to anti-tumor necrosis factor (TNF) therapy and
are enriched in synovial clonotypes.11 Teff resist-
ance to Treg cell-mediated suppression is also
recognised in RA.12
As for the regulatory arm, Treg cells are believed
to be reduced in numbers and dysfunctional in RA.
Certain therapies, such as those relying on anti-TNF,
can re-establish normal Treg cell counts and func-
tion.13 In JIA, discordant data have been reported
on the prevalence of Treg cells in the blood, while
most studies agree that they accumulate in the syn-
ovial fluid (SF).14 15 In addition, synovial Treg cells
seem able to suppress Teff proliferation and cytokine
production in vitro, that is, once removed from the
inflammatory milieu, suggesting that they are not
intrinsically dysfunctional.16 However, no data are
available on how current therapies affect Treg cell
phenotype and function in JIA. In this regard, recent
data demonstrate that Treg cells are a heterogeneous
population. Indeed, Treg cells comprise both acti-
vated CD45RA−FOXP3hi cells with enhanced sup-
pressive function and turnover as well as quiescent
CD45RA+ cells.17 Another Treg cell subset, defined
by the expression of HLA-DR, is endowed with
early contact-dependent suppressive function.18
Dissecting the role of the different subsets in disease
pathogenesis is crucial to understand the immuno-
logical mechanisms underlying unresponsiveness to
therapy and to develop more effective and targeted
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treatment regimens, which is the main goal of precision medicine.
Unfortunately, data are often lacking in human disease due to lim-
itations in the number and amount of available samples.
In this work, we demonstrate that a subset of bona fide,
antigen-stimulated and suppressive Treg cells expands during
active autoimmunity in JIA. Investigation of their TCR reper-
toire through next-generation sequencing demonstrates that
these Treg cells are enriched in synovial clonotypes, some of
which were shared with pathogenic Teff cells. Our work
uncovers an easily accessible pool of synovial Treg cells in the
circulation that might be used as a novel non-invasive diagnostic
tool, and proposes an innovative antigen-agnostic approach to
shed light on pathogenic mechanisms of autoimmune disease
and unresponsiveness to therapy.
MATERIALS AND METHODS
TCR sequencing
TCRβ CDR3 sequencing was performed by Adaptive
Biotechnologies. Statistical analysis of TCR repertoire datasets is
described in detail in previous reports.11 Briefly, each sample is
interpreted as a distribution of individuals (T cell genomes)
belonging to different species (TCR clonotypes). The similarity
between samples is determined by the number and frequencies
of shared clonotypes, using either productive nucleotide
sequences or amino acid sequences derived by in silico transla-
tion. The similarity between samples was calculated either using
the Chao-modified Jaccard index, which varies from 0 (com-
plete dissimilarity) to 1 (complete similarity), or by repeated
random subsampling at equal sample size (ie, equal number
of T cell genomes). The median percentage of clonotype
overlap resulting from 200 subsamples was then plotted.
Hierarchical clustering with single linkage and t-SNE dimen-
sionality reduction of TCR repertoires were performed using
the Chao-modified Jaccard index.11 19 TCR repertoire diver-
sities were determined using the Renyi index upon sample
size normalisation across a range of values of the α param-
eter, which puts more weight on abundant (α>1) or rare
(α<1) clonotypes.
Additional methodological details are available as online supple-
mentary information.
RESULTS
A subset of Treg cells is more represented in patients with
JIA unable to control inflammation
We investigated the phenotype of Treg cells in peripheral blood
samples of patients with JIA, collected before (T0) and after
(Tend) therapy,20 and stratified for responsiveness to therapy
based on whether they reached inactive disease (ID)21 or not
(NO ID) at Tend. All patients were NO ID at T0 but were
classified as prospective ID or prospective NO ID based on
their clinical activity at Tend. The percentage of Treg cells
was similar between ID and NO ID patients, both before
(ie, would be ID and would be NO ID, respectively) and after
therapy (figure 1A).
We explored whether previously described subsets of Treg
cells varied with clinical activity. The percentage of naive
CD45RA+ Treg cells was identical between ID and NO ID
patients, irrespective of the time point analysed (figure 1B). The
prevalence of activated CD45RA−FOXP3hi Treg cells was also
similar between the two groups (figure 1C). By contrast, the
percentage of HLA-DR+ Treg cells substantially decreased in ID
while slightly increasing in NO ID patients over the course of
the treatment, resulting in a more than doubled frequency of
these inflammation-associated (ia)Treg cells in NO ID patients as
compared with ID patients at Tend (figure 1D). Based on these
data, we hypothesised that the size of the iaTreg cell subset is
dynamically regulated: it expands during inflammation (ie, both
before therapy and in patients failing therapy), likely in an
effort to control autoreactivity, and it shrinks upon clinical
improvement (ie, in patients who reach ID upon treatment).
Therefore, iaTreg cells might be envisioned as a novel tool to
track responsiveness to therapy.
iaTreg cells are bona fide Treg cells endowed with
suppressive ability
To determine whether iaTreg cells are truly suppressive cells,
rather than Teff transiently upregulating FOXP3, we investigated
their commitment to the regulatory lineage by analysing the
methylation profile of the Treg cell-specific demethylated region
(TSDR) within the FOXP3 locus.22 23 Unlike FOXP3 expres-
sion, this epigenetic feature is absent in unstable Treg cells and
in FOXP3+ Teff.24 Both iaTreg cells and the rest of Treg cells
were as demethylated at their TSDR as Treg cells from healthy
donors (HD, figure 2A, B), indicating that they are bona fide
regulatory cells.
Previous reports indicate that HLA-DR expressing Treg cells
from HD are endowed with early contact-dependent suppressive
function.18 We found that also iaTreg cells from patients with
JIA are suppressive, to the same extent as the rest of Treg cells
(figure 2C).
Altogether, these findings support the notion that iaTreg cells
are genuinely tolerogenic and functionally competent.
Figure 1 A subset of regulatory T (Treg) cells is more represented in patients with juvenile idiopathic arthritis ( JIA) unable to control inflammation.
(A–C) Frequency of total Treg cells in blood CD4+ T cells (A), and frequency of CD45RA+ (B), CD45RA−FOXP3hi (C) or HLA-DR+ (D) in Treg cells of
patients with JIA. All patients were NO ID at T0, and were segregated based on their clinical activity at Tend. ID: (prospective) inactive disease; NO
ID: (prospective) active disease. Vertical lines represent SEM. n=10–13 per group, per time point. *p<0.05 (two-tailed unpaired t-test).
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iaTreg cells are activated Treg cells able to recirculate
through inflamed sites
Based on the observation that iaTreg cells expand during active
autoimmunity and are fully suppressive in vitro, we hypothe-
sised that these cells increase in numbers in an attempt to
restrain deranged effector mechanisms. To address this hypoth-
esis, we first characterised their migratory potential by looking
at chemokine receptors. Compared with the other Treg cells, a
larger fraction of iaTreg cells expressed the inflammatory tissue-
homing receptor CCR5, as opposed to the lymph node-homing
receptor CCR7 (figure 3A). This pattern of expression of che-
mokine receptors suggests that iaTreg cells have recently encoun-
tered the antigen, either in the lymph node upon priming, or in
the synovium upon reactivation. In either case, antigen recogni-
tion would induce iaTreg cell activation and proliferation; there-
fore, we investigated Ki67 (which marks active cell cycle),
Nur77 (an early marker of TCR signalling)25 and receptors
endowed with regulatory function, including cytotoxic T-
lymphocyte-associated protein-4 (CTLA-4), glycoprotein A
repetitions predominant (GARP) and CD39.1 Consistent with
our hypothesis of recent antigen encounter, a large proportion
of iaTreg cells expressed Ki67 (figure 3B). iaTreg cells also upre-
gulated Nur77, indicating that iaTreg cell proliferation is not
due to bystander activation but to TCR triggering (figure 3C).
In addition, when compared with the rest of Treg cells, many
more iaTreg cells displayed an activated phenotype, as indicated
by the induction of regulatory markers (figure 3D).
Altogether, our data suggest that iaTreg cells have recently
proliferated and become activated upon cognate antigen
encounter, and that they can recirculate between the blood and
the inflamed peripheral tissues.
iaTreg cells are enriched in synovial Treg cell clonotypes
To obtain conclusive evidence that blood iaTreg cells are indeed
migrating to (or escaping from) the synovium, we investigated
their TCR repertoires through next-generation sequencing of
CDR3 regions within the TCRβ chains (see online supplemen-
tary table S1). This approach enabled us to determine at single-
cell level whether iaTreg cells shared a substantial fraction of
clonotypes with synovial Treg cells.
We first confirmed that synovial Treg cells are committed to
the regulatory lineage by probing the epigenetic state of their
TSDR. Synovial Treg cells were as demethylated as blood Treg
cells, and comparable to Treg cells from HD (figure 4A, B),
demonstrating that they were bona fide regulatory cells.
We then investigated the diversity of the TCR repertoire of
iaTreg cells using in silico-translated (amino acid) and nucleotide
sequences, both yielding similar results (see figure 4C and
online supplementary figure S2). iaTreg cells displayed reduced
TCR diversity (lower Renyi index) compared with other Treg
cells, in line with the notion that iaTreg cells have expanded in
response to antigen stimulation. Interestingly, in some patients
iaTreg cells were as oligoclonal as synovial Treg cells (see online
supplementary figure S2).
Figure 2 iaTreg cells are bona fide Treg cells endowed with suppressive ability. (A) Methylation percentages of individual CpG sites in the FOXP3
the Treg cell-specific demethylated region (TSDR), colour-coded according to the legend, in Teff and Treg cells from representative male and female
NO ID patients. As a reference, the methylation profiles of cells from representative male and female healthy donors (HD) out of six are reported.
Treg cells are partially demethylated in females due to X-inactivation. Absolute coordinates of the FOXP3 gene according to the GRCh37/hg19
human genome assembly are indicated. (B) Summary of methylation percentages of iaTreg and other Treg cells (n=4 females and 4 males). (C) Teff
were activated with anti-CD3/CD28 and cocultured with either iaTreg or the rest of circulating Treg cells. Suppression of Teff activation relative to a
no-Treg cell control is reported. Each line corresponds to a patient. ns: not significant (two-tailed paired t-test). Teff, effector T; Treg, regulatory T;
iaTreg, inflammation-associated regulatory T.
Figure 3 iaTreg cells are activated Treg cells able to recirculate through inflamed sites. Differential marker expression by flow cytometry (A, B and D) or
qPCR (C) between iaTreg and other circulating Treg cells from NO ID patients at baseline. Each line corresponds to a patient. *p<0.05; **p<0.01;
***p<0.001; ****p<0.0001 (two-tailed paired t-test). Treg, regulatory T; iaTreg, inflammation-associated regulatory T.
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Finally, we investigated the TCR repertoire similarity between
synovial and iaTreg cells (figure 4D, F and online supplementary
figure S3) using two different strategies.11 First, we determined
the repertoire overlap between matched blood and synovial
samples. Synovial Treg cells shared a substantially higher frac-
tion of CDR3 sequences with iaTreg cells than with the rest of
circulating Treg cells (see figure 4D and online supplementary
figure S3A), demonstrating that iaTreg cells are enriched in syn-
ovial clonotypes. Second, we investigated the overall repertoire
similarity across the three cell types by using the Chao-modified
Jaccard index, which takes into account both the number of
shared species and their frequencies. This approach supported
our previous conclusion that the clonotypes of iaTreg cells are
more closely related to synovial Treg cells than to the rest of cir-
culating Treg cells (see figure 4E and online supplementary
figure S3B). Consistently, unsupervised clustering based on this
index segregated iaTreg cells apart from the rest of blood Treg
cells but together with synovial Treg cells within each patient
(see figure 4F and online supplementary figure S3C).
In summary, two independent analytical strategies led to the
conclusion that iaTreg cells comprise clonotypes recirculating
between the blood and the synovium.
The TCR repertoire of iaTreg cells is donor-specific and
partially shared with that of pathogenic Teff
In an effort to understand intraindividual and interindividual
variability of TCR rearrangements, we asked whether the TCR
repertoire of iaTreg cells shows convergence across patients, and
whether it is closer to the effector (suggestive of transdifferentia-
tion) or the regulatory lineage. To this aim, we compared the
TCR repertoires of blood and synovial Teff and Treg cells. Blood
Treg cells were segregated in iaTreg and other Treg cells. Blood
Teff was similarly segregated in circulating pathogenic-like lym-
phocytes (CPLs) or other Teff.11 We used a dimensionality reduc-
tion algorithm (t-Distributed Stochastic Neighbor Embedding
(t-SNE)) to produce a broad visualisation of the similarities
across TCR repertoires (see online supplementary figure S4A).
TCR repertoires clustered primarily by patient, confirming that
TCR repertoires vary widely across individuals, as also indicated
by hierarchical clustering (figure 4F). Then, within each patient,
Tcells clustered by lineage (Teff vs Treg cells).
Given the large differences across patients, we then visualised
similarities across cell subsets within each subject by plotting all
the pairwise distances between TCR repertoires as a heatmap. By
far, the greatest similarity was observed between iaTreg cells and
synovial Treg cells, and between CPLs and synovial Teff, respect-
ively (see online supplementary figure S4B). Interestingly, we
observed a gradient of TCR repertoire similarities between iaTreg
cells and the other Tcell subsets (see online supplementary figure
S4C). Indeed, iaTreg cells were most closely related to synovial
and other blood Treg cells, but distinct from non-CPL blood Teff
cells. In between these two extremes, iaTreg cells displayed some
degree of overlap with arthritis-associated synovial Teff and
blood CPLs.
Figure 4 iaTreg cells are enriched in synovial Treg cell clonotypes at amino acid level. (A) Methylation percentages of individual CpG sites in the
T cell-specific demethylated region (TSDR), colour-coded according to the legend, in Teff and Treg cells from representative male and female NO ID
patients. (B) Summary of methylation percentages of blood and synovial Treg cells (n=7 females and 4 males). (C–F) Next-generation sequencing of
TCRβ CDR3 sequences was performed on blood or synovial Treg cells of patients who had juvenile idiopathic arthritis ( JIA) with active disease. All
panels were built from in silico-translated (amino acid) sequences. (C) Summary of Renyi diversity indices of the TCR repertoires of iaTreg cells and
the rest of blood Treg cells at α=1. (D) Overlap of the TCR repertoires of iaTreg cells and the rest of blood Treg cells with that of synovial Treg cells
at equal sample size. (E) Summary of the pairwise distances between the TCR repertoires of iaTreg cells (or the rest of blood Treg cells) and those of
synovial Treg cells, computed as 1-Chao-modified Jaccard index. (F) Unsupervised hierarchical clustering based on TCR repertoire distances.
Each colour represents an individual patient. ***p<0.001; ****p<0.0001 (two-tailed paired t-test). HD, healthy donors; Teff, effector
T; Treg, regulatory T; iaTreg, inflammation-associated regulatory T.
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Altogether, our data suggest that the TCR repertoire of iaTreg
cells is largely private across patients and ontogenically related
to the Treg cell lineage. However, iaTreg cells share a detectable
fraction of TCRs with Teff subsets connected to arthritis,
whereas the bulk of ‘arthritis-inert’ blood Teff and Treg cells
show negligible TCR repertoire overlap with each other (see
online supplementary figure S4B).
iaTreg cells are increased in the blood of patients with
active RA
To address the question of whether iaTreg cells are associated
with active inflammation in JIA, and also in other pathological
conditions where effector mechanisms prevail over tolerance,
we tested their frequency in the blood of adult patients who
had active RA. When compared with healthy controls, patients
with RA displayed an impressive expansion of circulating iaTreg
cells (figure 5). Therefore, iaTreg cells are overrepresented
during active inflammation in both adult and juvenile auto-
immune arthritis.
DISCUSSION
In this work, we found that a subset of Treg cells is more preva-
lent in the blood of patients with JIA and active inflammation
compared with patients achieving ID. This subset comprises
bona fide activated and suppressive Treg cells able to recirculate
between the systemic circulation and the synovial microenviron-
ment. Our work provides several conceptual advances empower-
ing future investigations in the field of translational research at
large.
First, while Treg cells as a whole, as well as the naive
(CD45RA+) and the activated CD45RA−FOXP3hi Treg cell
subsets, are stable over the course of treatment, iaTreg cells
selectively persist in NO ID patients. Thus, abnormal features
arising in disease may be overlooked when focusing on unsegre-
gated populations, as the signal from (potentially small) relevant
subsets would be diluted by a large pool of clinically irrelevant
cells. This issue is critical, as most studies perform bulk
measurements (eg, transcriptomic profiling) on whole blood
Treg cells. In light of our data, we express concern that these
efforts may be unfruitful until the cell target is redefined.
Second, mouse T cells do not express MHC class II.26 This
lack severely limits the ability to experiment with iaTreg cells in
vivo, and is likely a reason why their role in autoimmune arth-
ritis has been overlooked so far. This disconnect underscores
that both animal and human research are necessary to under-
stand mechanisms of disease.
Third, the approach we devised to demonstrate the relevance
of iaTreg cells in autoimmunity is a conceptual shift from trad-
itional methods, which rely on antigen-based screening. These
approaches, originally developed for conventional T cells and
hindered by the low frequency of lymphocytes specific for any
given antigen, are even more challenging with Treg cells, due to
their low frequency in blood and the paucity of known Treg
cell-recognised self-antigens. These hurdles, coupled with the
small amount of blood withdrawn from juvenile patients, make
these approaches ill-suited to investigate Treg cell reactivity.
Rather than relying on prior antigen knowledge, we moved
from the observation that arthritogenic clonotypes are enriched
in the synovium.27–34 Thus, we compared synovial and circulat-
ing TCR repertoires at clonal resolution using next-generation
sequencing. We demonstrated that iaTreg cells are enriched in
clonotypes typical of synovial Treg cells, to the point that they
cosegregate with synovial Treg cells rather than with the other
blood Treg cells in unsupervised clustering. Our observations
endow HLA-DR with the novel role of pinpointing a reservoir
of synovial Treg cells in the peripheral circulation. Importantly,
TCR repertoires were largely private across individuals, consist-
ently with the mechanisms underlying HLA-driven positive
selection of newly rearranged TCRs. As such, the identification
of arthritis-associated clonotypes will likely require de novo
investigations of immune features distinctive of each subject.
iaTreg cells can empower such personalised investigations from
simple blood draws rather than expensive and increasingly rare
SF samples.
Lastly, iaTreg cells are expanded in active JIA, and also in
adult RA. The consistency of our findings in two distinct auto-
immune diseases highlights the clinical relevance of iaTreg cells
in conditions where immune regulation is ineffective. Further
investigations of this subset may yield critical insights into the
pathological mechanisms at play in human arthritis and, pos-
sibly, autoimmunity at large.
We have recently reported that a subset of recently activated,
proinflammatory Teff (CPLs) is expanded in this very same
cohort of patients resistant to anti-TNF therapy.11 As effector
and regulatory mechanisms are unbalanced during active arth-
ritis, we initially expected that the observed increase in activated
Teff would be matched by a corresponding decrease in Treg
cells. However, Treg cells as a whole do not differ between ID
and NO ID patients, but iaTreg cells are even expanded during
active inflammation. In addition, iaTreg cells and CPLs display a
similar expression pattern of chemokine receptors and markers
of activation. Although these findings are conceivable, as these
surface molecules are involved in pathways of T cell activation,
differentiation and migration common to Teff and Treg cells,
they raise the question of whether iaTreg cells are genuine regu-
latory cells. Our data show that iaTreg cells (i) are fully commit-
ted to the regulatory lineage, as demonstrated by their TSDR
demethylation, (ii) express high levels of membrane-bound pro-
teins associated with contact-dependent regulatory functions,
such as CTLA-4,35 (iii) are functionally suppressive and (iv) are
ontogenically related to the Treg cell lineage. Our results are
Figure 5 iaTreg cells are increased in the blood of patients with
active rheumatoid arthritis (RA). Frequency of iaTreg cell within the
whole Treg cell population in the blood of adult patients who had
active RA (DAS28-3>3.2). Each dot corresponds to a sample. Horizontal
red lines represent means, and error bars represent SEM. n=7 healthy
donors (HD) and 33 patients with RA. **p<0.01 (two-tailed unpaired
t-test). Treg, regulatory T; iaTreg, inflammation-associated regulatory T.
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consistent with previous data from normal donors demonstrat-
ing that HLA-DR+ Treg cells are endowed with early contact-
mediated suppressive ability.18 Therefore, iaTreg cells do not
appear intrinsically dysfunctional or epigenetically unstable.
Interestingly, iaTreg cells are actively proliferating upon TCR
triggering in the absence of overt infection, as indicated by high
prevalence of Ki67, reduced TCR repertoire diversity and
Nur77 upregulation. In addition, although iaTreg cells are onto-
genically related to Treg cells, they show some degree of TCR
repertoire overlap with arthritis-associated synovial Teff and
blood CPLs. This finding fits into the accepted paradigm
whereby modestly self-reactive TCRs escaping negative selection
give rise to either tolerogenic Treg cells or effector clonotypes
poised for autoimmunity.36 The expansion of iaTreg cells during
active inflammation may thus represent an attempt to counteract
the growth of pathogenic Teff. However, the clinical outcome of
NO ID patients indicates that iaTreg cells are unsuccessful, pos-
sibly because of extrinsic factors known to contribute to the
inability of Treg cells to suppress in vivo, such as the proinflam-
matory cytokine environment in the inflamed synovium15 and
the Teff resistance to Treg cell-mediated suppression.8–10 37
Therefore, normalising the inflamed synovial microenvironment
and the hyperactivation of the effector arm might help re-enable
deranged tolerogenic mechanisms.
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